title: Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus-pertussis and inactivated poliovirus vaccinations of childhood.
abstract: A Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) is capable of protecting infants against invasive H. influenzae diseases. Therefore it is very likely that it will be incorporated in routine vaccination schedules during the next few years. In order to test the suitability of simultaneous administration of PRP-D and other vaccines we administered it to 25 infants mixed with diphtheria-tetanus-pertussis vaccine at 3, 4 and 6 months and simultaneously, but in a separate syringe, with inactivated polio vaccine at 12 months. A comparison group of equal size received only diphtheria-tetanus-pertussis and inactivated poliovirus vaccines. The concentration of postvaccination antibodies to diphtheria toxoid was 0.411 IU/ml in the group that received PRP-D vs. 0.352 IU/ml in the comparison group, to tetanus toxoid 3.666 vs. 3.668 IU/ml and the neutralization titer to poliovirus type 1 was 370 vs. 320 units in the comparison group, to type 2 titer values were 230 vs. 270 units and to type 3, respectively, 210 vs. 290 units. Thus the seroresponse to antigens in routine vaccines was not affected by the presence of PRP-D in the vaccination schedule, and PRP-D can safely and effectively be included in the vaccination schedule of infancy.
authors.affiliation: National Public Health Institute, Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Eskola
authors.forename: H
authors.initials: H
authors.lastname: Käyhty
authors.forename: L K
authors.initials: LK
authors.lastname: Gordon
authors.forename: T
authors.initials: T
authors.lastname: Hovi
authors.forename: M
authors.initials: M
authors.lastname: Stenvik
authors.forename: P R
authors.initials: PR
authors.lastname: Rönnberg
authors.forename: E
authors.initials: E
authors.lastname: Kela
authors.forename: H
authors.initials: H
authors.lastname: Peltola
mesh_terms: D001428:Bacterial Vaccines / Q000008:administration & dosage*; D004168:Diphtheria Toxoid / Q000008:administration & dosage*; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations / Q000008:administration & dosage; D005387:Finland; D018073:Haemophilus Vaccines; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D010567:Pertussis Vaccine / Q000008:administration & dosage*; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage*; D013745:Tetanus Toxoid / Q000008:administration & dosage*; D014613:Vaccines, Attenuated / Q000008:administration & dosage
chemical_list: D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate; D010567:Pertussis Vaccine; D011054:Poliovirus Vaccine, Inactivated; D013745:Tetanus Toxoid; D014613:Vaccines, Attenuated